ClinicalTrials.gg
CompletedNCT06805565Updated Jul 8, 2026

A Study of ONO-1110 in Patients With Social Anxiety Disorder

A Phase 2 interventional study of ONO-1110 and Placebo in Social Anxiety Disorder (SAD), sponsored by Ono Pharmaceutical Co., Ltd.. Completed at 27 sites in Japan. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-08.

Sponsored by Ono Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
115
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

To Evaluate the Efficacy and Safety of ONO-1110 in Patients with Social Anxiety Disorder

02

Conditions studied

  • Social Anxiety Disorder (SAD)

Browse trials for

03

In context

Phobia, Social

368 studies on the registry are indexed under Phobia, Social; 59 are open to participants now.

This study's enrollment of 115 is above the median of 76 across 339 interventional studies indexed under Phobia, Social.

Browse Phobia, Social studies →

Lead sponsor

Ono Pharmaceutical Co., Ltd. is the lead sponsor of 49 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Japanese participants (sex not specified)
  2. Participants who, in the opinion of the principal (or sub-investigator), are capable of understanding the content of the clinical trial and complying with its requirements
  3. Participants diagnosed with social anxiety disorder based on (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision) criteria, as determined through an interview using the M.I.N.I. (Mini-international neuropsychiatric interview)
  4. Outpatients
  5. Participants with a LSAS-J (Liebowitz Social Anxiety Scale Japanese version) total score of 70 or higher and a CGI-S (Clinical global impression-Severity) score of 4 or higher

Exclusion criteria

Exclusion Criteria:

  1. Participants with a current or past history of psychiatric or neurological disorders that meet any of the following criteria:

    • Participants with a comorbid psychiatric disorder other than social anxiety disorder as defined by (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision) (assessed using the M.I.N.I. (Mini-international neuropsychiatric interview))
    • Participants with a comorbid or past history of schizophrenia or other psychotic disorders as defined by DSM-5-TR (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision)
    • Participants with neurodevelopmental disorders, neurocognitive disorders, or personality disorders (excluding avoidant personality disorder) as defined by DSM-5-TR
  2. Participants who have been primarily diagnosed with a disorder other than social anxiety disorder according to DSM-5-TR (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision) criteria within 24 weeks prior to screening
  3. Participants with a MADRS (Montgomery Åsberg Depression Rating Scale) total score of 15 or higher
  4. Participants who, in the opinion of the principal (or sub-investigator), have not responded to at least two different SSRIs (Selective serotonin reuptake inhibitor), each administered at an adequate dose for at least 10 weeks, in treating social anxiety disorder
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
115 participants (actual)

Study arms

  • Experimental
    ONO-1110

    Drug: ONO-1110 · Drug: Placebo

  • Placebo comparator
    Placeo

    Drug: ONO-1110 · Drug: Placebo

Interventions

  • ONO-1110 tablets once a day

  • DrugPlacebo

    Placebo tablets once daily

06

What researchers measure

Primary outcomes

  1. Change in L-SAS J(Liebowitz Social Anxiety Scale Japanese version) total score from baseline to Week 12 of the treatment period

    Time frame: Up to 19 weeks

Secondary outcomes

  1. The transition of LSAS-J(Liebowitz Social Anxiety Scale Japanese version) total score from baseline to Week 8 of the treatment period

    Time frame: Up to 19 weeks

  2. The transition of LSAS-J(Liebowitz Social Anxiety Scale Japanese version) Fear or Anxiety score from baseline to Week 8 of the treatment period

    Time frame: Up to 19 weeks

  3. The transition of LSAS-J(Liebowitz Social Anxiety Scale Japanese version) Avoidance score from baseline to Week 8 of the treatment period

    Time frame: Up to 19 weeks

  4. Responder rates of LSAS-J(Liebowitz Social Anxiety Scale Japanese version) total score at 1, 2, 4, 6, 8,10and 2 weeks of the treatment period

    Responder is defined as a reduction of 30% or more in LSAS-J(Liebowitz Social Anxiety Scale Japanese version)total score from baseline

    Time frame: Up to 19 weeks

  5. Remitted patient rates of LSAS-J(Liebowitz Social Anxiety Scale Japanese version) total score at 1, 2, 4, 6, 8, 10 and 12 weeks of the treatment period

    Remitted patient is defined as a LSAS-J(Liebowitz Social Anxiety Scale Japanese version) total score of 30 or less.

    Time frame: Up to 19 weeks

  6. Transition of CGI-S(Clinical Global Impression of illness Severity) score from baseline to Week 12 of the treatment period

    Time frame: Up to 19 weeks

  7. Transition of SDISS(Sheehan Disability Scale) score from baseline to Week 12 of the treatment period

    Time frame: Up to 19 weeks

  8. Plasma ONO-1110 concentrations

    Time frame: Up to 19 weeks

  9. Adverse Events

    Time frame: Up to 19 weeks

07

Study locations

27 sites
  • Aisakura Clinic
    Fukuoka, Japan
  • AK Clinic
    Fukuoka, Japan
  • Hiro Mental Clinic
    Fukuoka, Japan
  • Hirota Clinic
    Fukuoka, Japan
  • Kokorono Clinic Hirao
    Fukuoka, Japan
  • Kokura Mental Clinic
    Fukuoka, Japan
  • Mental Clinic Sakurazaka
    Fukuoka, Japan
  • Shinseikai Kaku Mental Clinic
    Fukuoka, Japan
  • Uematsu Mental Clinic
    Fukuoka, Japan
  • Ichikawa Clinic
    Gunma, Japan
  • Higashi-Sapporo Mental Clinic
    Hokkaido, Japan
  • Kawamura Mental Clinic
    Hokkaido, Japan
  • Minami1jo Mental Clinic
    Hokkaido, Japan
  • Sapporo Kobushi Clinic
    Hokkaido, Japan
  • Shimode Mental Clinic
    Hokkaido, Japan
  • Tatsuta Clinic
    Hyōgo, Japan
  • Yutaka Clinic
    Kanagawa, Japan
  • Ai Clinic
    Miyazaki, Japan
  • Inoue Clinic
    Osaka, Japan
  • Yamaguchi Mental Clinic
    Tokushima, Japan
  • Harai Clinic
    Tokyo, Japan
  • Iidabashi Mental Clinic
    Tokyo, Japan
  • Ikebukuro Olive Mental Clinic
    Tokyo, Japan
  • Maynds Tower Mental Clinic
    Tokyo, Japan
  • Meguroeki Higashiguchi Mental Clinic
    Tokyo, Japan
  • Monzen-nakacho Mental Clinic
    Tokyo, Japan
  • Sangenjaya Nakamura Mental Clinic
    Tokyo, Japan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2025 to primary completion in May 2026, 15 months.

Of 15 phase 2 interventional studies under Phobia, Social, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 15 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2025
First posted
Feb 3, 2025
StartActual
Jan 31, 2025
Primary completionActual
May 25, 2026
CompletionActual
May 25, 2026
Last update
Jul 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06805565
Responsible party
Sponsor
First posted
Feb 3, 2025
Start date
Jan 31, 2025
Primary completion
May 25, 2026
Completion
May 25, 2026
Last update
Jul 8, 2026

Study contacts

Project Leader
study director · Ono Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ONO-1110

Start the discussion